Role of advanced glycation on aggregation and DNA binding properties of α-synuclein

Journal of Alzheimer's Disease

Volumn 24, Issue SUPPL. 2, 2011, Pages 211-221

  Padmaraju, Vasudevaraju ^a   Bhaskar, Jamuna J ^a   Prasada Rao, Ummiti J S ^a   Salimath, Paramahans V ^a   Rao, K S ^a,b  

^a CENTRAL FOOD TECHNOLOGICAL RESEARCH INSTITUTE   (India)

^b Tecnología e innovación   (Panama)

Author keywords

AGEs; DNA conformation; glycation; Parkinson's disease; protein aggregation; synuclein

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALPHA SYNUCLEIN; DEOXYRIBONUCLEASE I; DNA; ETHIDIUM BROMIDE; FRUCTOSAMINE; METHYLGLYOXAL; TYROSINE;

ARTICLE; COMPLEX FORMATION; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DNA CONFORMATION; DNA SUPERCOILING; FLUORESCENCE; MELTING POINT; MOLECULAR STABILITY; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN CONFORMATION; PROTEIN DNA BINDING; PROTEIN GLYCOSYLATION;

EID: 79955657305     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2011-101965     Document Type: Article

References (51)

1. Gallagher DA, Schapira AH (2009) Etiopathogenesis and treatment of Parkinson's disease. Curr Top Med Chem 9, 860-868.
2. Bisaglia M, Mammi S, Bubacco L (2009) Structural insights on physiological functions and pathological effects of alphasynuclein. FASEB J 23, 329-340.
3. Fasano M, Lopiano L (2008) Alpha-synuclein and Parkinson's disease: a proteomic view. Expert Rev Proteomics 5, 239-248. (Pubitemid 351670928)
4. Jellinger KA (2009) A critical evaluation of current staging of alpha-synuclein pathology in Lewy body disorders. Biochim Biophys Acta 1792, 730-740.
5. Maroteaux L, Campanelli JT, Scheller RH (1988) Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J Neurosci 8, 2804-2815.
6. Hegde ML, Vasudevaraju P, Rao KJ (2010) DNA induced folding/fibrillation of alpha-synuclein: new insights in Parkinson's disease. Front Biosci 15, 418-436.
7. Bayer TA, Jäkälä P, Hartmann T, Egensperger R, Buslei R, Falkai P, Beyreuther K (1999) Neural expression profile of alpha-synuclein in developing human cortex. Neuroreport 10, 2799-2803. (Pubitemid 30004108)
8. Kaplan B, Ratner V, Haas E (2003) Alpha-synuclein: its biological function and role in neurodegenerative diseases. JMol Neurosci 20, 83-92. (Pubitemid 36693813)
9. Di Rosa G, Puzzo D, Sant'Angelo A, Trinchese F, Arancio O (2003) Alpha-synuclein: between synaptic function and dysfunction. Histol Histopathol 18, 1257-1266.
10. Schneider BL, Seehus CR, Capowski EE, Aebischer P, Zhang SC, Svendsen CN (2007) Over-expression of alpha-synuclein in human neural progenitors leads to specific changes in fate and differentiation. Hum Mol Genet 16, 651-666. (Pubitemid 46591118)
11. Mori F, Tanji K, Yoshimoto M, Takahashi H, Wakabayashi K (2002) Immunohistochemical comparison of alpha-and beta-synuclein in adult rat central nervous system. Brain Res 941, 118-126. (Pubitemid 34603290)
12. Specht CG, Tigaret CM, Rast GF, Thalhammer A, Rudhard Y, Schoepfer R (2005) Subcellular localisation of recombinant alpha-and gamma-synuclein. Mol Cell Neurosci 28, 326-334. (Pubitemid 40202593)
13. Yu S, Zuo X, Li Y, Zhang C, Zhou M, Zhang YA, Uéda K, Chan P (2004) Inhibition of tyrosine hydroxylase expression in alpha-synuclein- transfected dopaminergic neuronal cells. Neurosci Lett 367, 34-39. (Pubitemid 39078779)
14. Kontopoulos E, Parvin JD, Feany MB (2006) Alpha-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity. Hum Mol Genet 15, 3012-3023. (Pubitemid 44530705)
15. Hegde ML, Gupta VB, Anitha M, Harikrishna T, Shankar SK, Muthane U, Subba Rao K, Jagannatha Rao KS (2006) Studies on genomic DNA topology and stability in brain regions of Parkinson's disease. Arch Biochem Biophys 449, 143-156.
16. Hegde ML, Jagannatha Rao KS (2003) Challenges and complexities of alpha-synuclein toxicity: new postulates in unfolding the mystery associated with Parkinson's disease. Arch Biochem Biophys 418, 169-178. (Pubitemid 37159383)
17. Hegde ML, Rao KS (2007) DNA induces folding in alpha-synuclein: understanding the mechanism using chaperone property of osmolytes. Arch Biochem Biophys 464, 57-69. (Pubitemid 47088357)
18. Cherny D, Hoyer W, Subramaniam V, Jovin TM (2004) Double-stranded DNA stimulates the fibrillation of alpha-synuclein in vitro and is associated with the mature fibrils: an electron microscopy study. J Mol Biol 344, 929-938. (Pubitemid 39491240)
19. Goers J, Manning-Bog AB, McCormack AL, Millett IS, Doniach S, Di Monte DA, Uversky VN, Fink AL (2003) Nuclear localization of alpha-synuclein and its interaction with histones. Biochemistry 42, 8465-8471. (Pubitemid 36875412)
20. Waxman EA, Giasson BI (2009) Molecular mechanisms of alpha-synuclein neurodegeneration. Biochim Biophys Acta 1792, 616-624.
21. Uversky VN, Eliezer D (2009) Biophysics of Parkinson's disease: structure and aggregation of alpha-synuclein. Curr Protein Pept Sci 10, 483-499.
22. Beyer K, Ariza A (2007) Protein aggregation mechanisms in synucleinopathies: commonalities and differences. J Neu-ropathol Exp Neurol 66, 965-974. (Pubitemid 350060365)
23. Negre-Salvayre A, Salvayre R, Augé N, Pamplona R, Portero-Otin M (2009) Hyperglycemia and glycation in diabetic complications. Antioxid Redox Signal 11, 3071-3109.
24. Sensi M, Pricci F, Andreani D, Di Mario U (1991) Advanced nonenzymatic glycation endproducts (AGE): their relevance to aging and the pathogenesis of late diabetic complications. Diabetes Res 16, 1-9.
25. Sandyk R (1993) The relationship between diabetes mellitus and Parkinson's disease. Int J Neurosci 69, 125-130.
26. Münch G, Lüth HJ, Wong A, Arendt T, Hirsch E, Ravid R, Riederer P (2000) Crosslinking of alpha-synuclein by advanced glycation endproducts-an early pathophysiologi-cal step in Lewy body formation? J Chem Neuroanat 20, 253-257. (Pubitemid 32162884)
27. Shaikh S, Nicholson LF (2008) Advanced glycation end products induce in vitro cross-linking of alpha-synuclein and accelerate the process of intracellular inclusion body formation. J Neurosci Res 86, 2071-2082.
28. Jenner P (2003) Oxidative stress in Parkinson's disease. Ann Neurol 53 Suppl 3, S26-S36; discussion S36-S38.
29. Brownlee M, Vlassara H, Cerami A (1984) Nonenzymatic glycosylation and the pathogenesis of diabetic complications. Ann Intern Med 101, 527-537. (Pubitemid 14018054)
30. Desai KM, Chang T, Wang H, Banigesh A, Dhar A, Liu J, Untereiner A, Wu L (2010) Oxidative stress and aging: is methylglyoxal the hidden enemy? Can J Physiol Pharmacol 88, 273-284.
31. Kuhla B, Lüth HJ, Haferburg D, Boeck K, Arendt T, Münch G (2005) Methylglyoxal, glyoxal, and their detoxification in Alzheimer's disease. Ann N Y Acad Sci 1043, 211-216. (Pubitemid 41123908)
32. Koutsilieri E, Scheller C, Grünblatt E, Nara K, Li J, Riederer P (2002) Free radicals in Parkinson's disease. J Neurol 249 Suppl 2, II1-5. (Pubitemid 35025128)
33. Jomova K, Vondrakova D, Lawson M, Valko M (2010) Metals, oxidative stress and neurodegenerative disorders. Mol Cell Biochem 345, 91-104.
34. Vicente Miranda H, Outeiro TF (2010) The sour side of neurodegenerative disorders: the effects of protein glycation. J Pathol 221, 13-25.
35. Ko SY, Lin YP, Lin YS, Chang SS (2010) Advancedglycation end products enhance amyloid precursor protein expression by inducing reactive oxygen species. Free Radic Biol Med 49, 474-480.
36. Fang F, Lue LF, Yan S, Xu H, Luddy JS, Chen D, Walker DG, Stern DM, Yan S, Schmidt AM, Chen JX, Yan SS (2010) RAGE-dependent signaling in microglia contributes to neuroinflammation, Abeta accumulation, and impaired learning/memory in a mouse model of Alzheimer's disease. FASEB J24, 1043-1055.
37. Nadig G, Ratnaparkhi GS, Varadarajan R, Vishveshwara S (1996) Dynamics ofribonuclease A and ribonuclease S: computationalandexperimentalstudies.Protein Sci5, 2104-2114.
38. Fontana A, Zambonin M, Polverino de Laureto P, De Filippis V, Clementi A, Scaramella E (1997) Probing the conformational state of apomyoglobin by limited proteolysis. J Mol Biol 266, 223-230. (Pubitemid 27171010)
39. Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227, 680-685.
40. Thomas TJ, Bloomfield VA (1985) Quasielastic laser light scattering and electron microscopy studies of the conformational transitions and condensation of poly(dA-dT).poly(dA-dT). Biopolymers 24, 2185-2194. (Pubitemid 16180662)
41. Scatchard G (1949) The attraction of proteins for small molecules and ions. Ann N Y Acad Sci 51, 660-672.
42. Chatterjee B, Rao GRK (1994) Superhelical density of goat mitochondrial DNA: Fluorescent studies. Indian J Biochem Biophys 31, 77-79.
43. Uversky VN, Li J, Fink AL (2001) Metal-triggered struc-tural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular NK between Parkin-son's disease and heavy metal exposure. J Biol Chem 276, 44284-44296.
44. Gray DM, Taylor TN, Lang D (1978) Dehydrated circular DNA: circular dichroism of molecules in ethanolic solutions. Biopolymers 17, 145-157. (Pubitemid 8275362)
45. Duracková Z (2010) Some current insights into oxidative stress. Physiol Res 59, 459-469.
46. Castellani R, Smith MA, Richey PL, Perry G (1996) Glycox-idation and oxidative stress in Parkinson disease and diffuse Lewy body disease. Brain Res 737, 195-200. (Pubitemid 26366614)
47. Choi YG, Lim S (2010)N()-(carboxymethyl)lysinelinkageto α-synuclein and involvement of advanced glycation end prod-ucts in α-synuclein deposits in an MPTP-intoxicated mouse model.Biochimie92, 1379-1386.
48. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M (1997) Alpha-synuclein inLewy bodies. Nature 388, 839-840.
49. Sian J, Dexter DT, Lees AJ, Daniel S, Agid Y, Javoy-Agid F, Jenner P, Marsden CD (1994) Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol 36, 348-355. (Pubitemid 24280055)
50. Lee D, Park CW, Paik SR, Choi KY (2009) The modifica-tion of alpha-synuclein by dicarbonyl compounds inhibits its fibril-formingprocess. Biochim Biophys Acta 1794, 421-430.
51. Chen L, Wei Y, Wang X, He R (2010) Ribosylation rapidly induces alpha-synuclein to form highly cytotoxic molten globules of advanced glycation end products. PLoS One 5, e 9052.